Research programme: P300/CBP inhibitors - CellCentric

Drug Profile

Research programme: P300/CBP inhibitors - CellCentric

Alternative Names: CCS 1477

Latest Information Update: 07 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CellCentric
  • Class Antineoplastics; Imidazoles; Isoxazoles; Pyridines; Small molecules
  • Mechanism of Action P300-CBP transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Jun 2017 Preclinical data in Cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Apr 2017 Preclinical data in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 16 Feb 2017 CellCentric plans a clinical trial for Cancer in USA and the United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top